BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 4150738)

  • 1. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G; Halle-Pannenko O; Bourut C
    Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
    Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
    Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
    [No Abstract]   [Full Text] [Related]  

  • 3. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.
    Mathé G; Kamel M; Dezfulian M; Halle-Pannenko O; Bourut C
    Cancer Res; 1973 Sep; 33(9):1987-97. PubMed ID: 4146853
    [No Abstract]   [Full Text] [Related]  

  • 4. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
    Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
    Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCG immunotherapy of rat tumors of defined immunogenicity.
    Baldwin RW; Pimm MV
    Natl Cancer Inst Monogr; 1973 Dec; 39():11-9. PubMed ID: 4595312
    [No Abstract]   [Full Text] [Related]  

  • 6. The second generation of EORTC-ECIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract.
    Mathe G; Halle-Pannenko O; Florentin I; Bruley-Rosset M; Kamel M; Hiu IJ; Bourut C
    Eur J Cancer (1965); 1975 Nov; 11(11):801-7. PubMed ID: 767112
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy of guinea pig cancer with BCG.
    Zbar B
    Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy of chronic myelocytic leukemia.
    Sokal JE; Aungst CW; Grace JT
    Natl Cancer Inst Monogr; 1973 Dec; 39():195-8. PubMed ID: 4595316
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
    Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
    [No Abstract]   [Full Text] [Related]  

  • 11. Activated macrophages and the antitumor action of BCG.
    Alexander P
    Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunotherapy of cancer with BCG].
    Yamamura Y; Azuma I
    Nihon Rinsho; 1974 Mar; 32(3):542-53. PubMed ID: 4603604
    [No Abstract]   [Full Text] [Related]  

  • 13. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprophylaxis and treatment of leukemia in AKR mice: repetitive use of BCG.
    Mardiney MR; Ungaro PC; Drake WP
    Natl Cancer Inst Monogr; 1973 Dec; 39():89-90. PubMed ID: 4595329
    [No Abstract]   [Full Text] [Related]  

  • 15. An experimental model for immunotherapy of cancer.
    Zbar B; Ribi E; Rapp HJ
    Natl Cancer Inst Monogr; 1973 Dec; 39():3-9. PubMed ID: 4595326
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy.
    Mathé G; Florentin I; Olsson L; Bruley-Rosset M; Schulz J; Kiger N; Orbach-Arbouys S; Schwarzenberg L; Pouillart P; de Vassal F
    Cancer Treat Rep; 1978 Nov; 62(11):1613-21. PubMed ID: 103616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental and clinical trials with BCG immunotherapy.
    Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL
    Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cancer immunotherapy with BCG cell-wall skeleton (author's transl)].
    Azuma I; Yamamura Y
    Tanpakushitsu Kakusan Koso; 1978 May; 23(6):625-40. PubMed ID: 211546
    [No Abstract]   [Full Text] [Related]  

  • 19. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease.
    Mathé G; Weiner R; Pouillart P; Schwarzenberg L; Jasmin C; Schneider M; Hayat M; Amiel JL; de Vassal F; Rosenfeld C
    Natl Cancer Inst Monogr; 1973 Dec; 39():165-75. PubMed ID: 4595314
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy of human leukemia.
    Baker MA; Taub RN
    Mt Sinai J Med; 1972; 39(6):548-65. PubMed ID: 4565179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.